New research has discovered a link between dietary zinc intake and protection against Streptococcus pneumoniae, suggesting it aids the immune system.
Browsing: Disease Area > Bacterial
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
The first chlamydia vaccine to reach Phase I clinical trials has been observed to be safe and immunogenic in 35 women.
Researchers discover Clostridium difficile is evolving due to genetic changes that allow it to thrive on the Western diet and evade disinfectants making it highly adapted to spread in hospitals.
Coagulation factors, which normally function to clot blood, have been demonstrated to have antibacterial action against Gram-negative bacteria in vitro and in mouse models.
In a study of healthy infants, researchers discover exposure to C. difficile in infancy may provide natural immunization later in childhood.
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Role of two-component regulatory systems in bacterial antibiotic resistance’, as we ask the authors about the mechanisms of two-component regulatory systems and what potential these could hold for drug development.
Research suggests that in the UK, new cases of tick-borne Lyme disease could be three-times higher than previous estimates, possibly exceeding 8000 cases in 2019.